(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.47%) $27.23
(0.41%) $924.25
(0.32%) $0.935
(0.80%) $11.04
(0.18%) $0.801
(-0.32%) $91.87
Live Chart Being Loaded With Signals
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform...
Stats | |
---|---|
Today's Volume | 1.75M |
Average Volume | 263 314 |
Market Cap | 2.33M |
EPS | $0 ( 2024-03-18 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.0194 |
ATR14 | $0.141 (69.42%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-05-05 | Lau Johnson Yiu Nam | Buy | 8 382 | Common Stock |
2023-05-05 | Kwan Rudolf | Buy | 3 603 | Common Stock |
2023-05-05 | Cook Timothy Devere | Buy | 368 | Common Stock |
2023-04-21 | Wu Jinn | Buy | 6 513 | Common Stock |
2023-04-21 | Vierling John | Buy | 6 513 | Common Stock |
INSIDER POWER |
---|
94.67 |
Last 100 transactions |
Buy: 1 577 577 | Sell: 76 746 |
Volume Correlation
Athenex Inc Correlation
10 Most Positive Correlations | |
---|---|
RUBY | 0.962 |
VERU | 0.948 |
AGIL | 0.946 |
CYXT | 0.946 |
GLG | 0.944 |
PRPL | 0.943 |
TTGT | 0.943 |
TCPC | 0.941 |
NCBS | 0.941 |
BSBK | 0.939 |
10 Most Negative Correlations | |
---|---|
SWAV | -0.955 |
ISRG | -0.954 |
HBIO | -0.95 |
LMRKO | -0.948 |
TYHT | -0.946 |
VRTX | -0.945 |
CREX | -0.943 |
LMRKP | -0.942 |
ALXN | -0.942 |
ITCI | -0.94 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Athenex Inc Correlation - Currency/Commodity
Athenex Inc Financials
Annual | 2022 |
Revenue: | $102.82M |
Gross Profit: | $26.70M (25.97 %) |
EPS: | $-15.13 |
FY | 2022 |
Revenue: | $102.82M |
Gross Profit: | $26.70M (25.97 %) |
EPS: | $-15.13 |
FY | 2021 |
Revenue: | $120.18M |
Gross Profit: | $37.78M (31.43 %) |
EPS: | $-1.920 |
FY | 2020 |
Revenue: | $144.39M |
Gross Profit: | $49.04M (33.96 %) |
EPS: | $-1.720 |
Financial Reports:
No articles found.
Athenex Inc
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in cutaneous angiosarcoma, advanced gastric cancer, and advanced solid malignancies. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company is developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product, which is in a phase I clinical trial for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for advanced hepatocellular carcinomas, as well as TCRT-ESO-A2, an autologous T cell receptor (TCR)-T cell therapy that is in phase 1 clinical trial for solid tumors. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract; and has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators